Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for liver disease: new drug trial targets PBC symptoms

NCT ID NCT06427395

Ongoing Disease control Sponsor: Zydus Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and helps control the disease. About 102 adults who completed a previous PBC study will take the drug and be monitored for side effects and liver health improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS

Contacts and locations

Locations

  • Zydus AR001

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1118AAT, Argentina

  • Zydus AR003

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1430CKE, Argentina

  • Zydus AR004

    Pilar, Buenos Aires, B1629ODT, Argentina

  • Zydus AR005

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1425BGC, Argentina

  • Zydus AR006

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1221ADC, Argentina

  • Zydus AR007

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina

  • Zydus TR004

    Ankara, 06800, Turkey (Türkiye)

  • Zydus TR005

    Bursa, 16059, Turkey (Türkiye)

  • Zydus TR015

    Melikgazi, 38039, Turkey (Türkiye)

  • Zydus TR016

    Altındağ, 06230, Turkey (Türkiye)

  • Zydus TR017

    Cebeli, 06620, Turkey (Türkiye)

  • Zydus US001

    Indianapolis, Indiana, 46202, United States

  • Zydus US002

    Charlotte, North Carolina, 28204, United States

  • Zydus US005

    Miami, Florida, 33136, United States

  • Zydus US006

    Lakewood Rch, Florida, 34211, United States

  • Zydus US011

    Pasadena, California, 91105, United States

  • Zydus US013

    Los Angeles, California, 90048, United States

  • Zydus US016

    Charlottesville, Virginia, 22908, United States

  • Zydus US020

    Marietta, Georgia, 30060, United States

  • Zydus US022

    Aurora, Colorado, 80045, United States

  • Zydus US027

    Jacksonville, Florida, 32224, United States

  • Zydus US031

    Murray, Utah, 84107, United States

  • Zydus US033

    Seattle, Washington, 98105, United States

  • Zydus US035

    Rochester, New York, 14642, United States

  • Zydus US037

    New Haven, Connecticut, 06520, United States

  • Zydus US039

    Richmond, Virginia, 23298, United States

  • Zydus US042

    Houston, Texas, 77030, United States

  • Zydus US043

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.